US equities
|
SPCX
$175.00
▲+2.29%
NVDA
$242.40
▲+1.47%
MU
$1,063.57
▼-0.04%
MRVL
$291.83
▲+7.59%
AMD
$648.91
▲+2.72%
SNDK
$1,668.14
▼-2.11%
TSLA
$380.94
▲+0.58%
AVGO
$376.05
▲+3.73%
SPCX
$175.00
▲+2.29%
NVDA
$242.40
▲+1.47%
MU
$1,063.57
▼-0.04%
MRVL
$291.83
▲+7.59%
AMD
$648.91
▲+2.72%
SNDK
$1,668.14
▼-2.11%
TSLA
$380.94
▲+0.58%
AVGO
$376.05
▲+3.73%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Galderma
< Previous
1
2
3
Next >
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
August 13, 2024
From
Galderma
Via
Business Wire
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
August 05, 2024
From
Galderma
Via
Business Wire
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
July 30, 2024
From
Galderma
Via
Business Wire
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance
July 25, 2024
From
Galderma
Via
Business Wire
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
July 09, 2024
From
Galderma
Via
Business Wire
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
June 19, 2024
From
Galderma
Via
Business Wire
Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
May 23, 2024
From
Galderma
Via
Business Wire
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
March 19, 2024
From
Galderma
Via
Business Wire
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
March 10, 2024
From
Galderma
Via
Business Wire
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
February 29, 2024
From
Galderma
Via
Business Wire
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
February 28, 2024
From
Galderma
Via
Business Wire
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
February 14, 2024
From
Galderma
Via
Business Wire
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
February 08, 2024
From
Galderma
Via
Business Wire
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
February 07, 2024
From
Galderma
Via
Business Wire
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
February 02, 2024
From
Galderma
Via
Business Wire
IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position
January 25, 2024
From
Galderma
Via
Business Wire
Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
January 22, 2024
From
Galderma
Via
Business Wire
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
January 17, 2024
From
Galderma
Via
Business Wire
Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines
November 30, 2023
From
Galderma
Via
Business Wire
Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories
November 21, 2023
From
Galderma
Via
Business Wire
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
October 13, 2023
From
Galderma
Via
Business Wire
Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis
October 11, 2023
From
Galderma
Via
Business Wire
EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
October 04, 2023
From
Galderma
Via
Business Wire
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
October 02, 2023
From
Galderma
Via
Business Wire
Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology
July 27, 2023
From
Galderma
Via
Business Wire
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4
July 04, 2023
From
Galderma
Via
Business Wire
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology
June 28, 2023
From
Galderma
Via
Business Wire
Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round
June 26, 2023
From
Galderma
Via
Business Wire
Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables
April 19, 2023
From
Galderma
Via
Business Wire
AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio
March 30, 2023
From
Galderma
Via
Business Wire
< Previous
1
2
3
Next >
